DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the EMCURE PHARMACEUTICALS L (EMCURE) share price today?

EMCURE PHARMACEUTICALS L (EMCURE) is trading at ₹1,783.2 on the NSE, down 1.08% on the day. Source: DocStoX.

What is the PE ratio of EMCURE PHARMACEUTICALS L?

EMCURE PHARMACEUTICALS L has a price-to-earnings (PE) ratio of 36.6 in the Healthcare sector.

What is the market capitalisation of EMCURE PHARMACEUTICALS L?

EMCURE PHARMACEUTICALS L has a market capitalisation of approximately ₹33,810 crore.

EMCURE PHARMACEUTICALS L

EMCURE·NSE·Healthcare

₹1,783.20▼ -19.50 (-1.08%)

Healthcare · Pharmaceuticals

High-quality returns — 20% on equity

NIFTY 500NIFTY SMALLCAP 250

Day₹1751.00

₹1814.00

52W₹1260

₹194476%

Open

₹1802.70

High

₹1814.00

Low

₹1751.00

Prev Close

₹1802.70

Volume

2.40L

VWAP

₹1786.33

Snapshot

Key fundamentals

Market Cap

₹33,810 Cr

P/E Ratio

36.57Expensive

P/B Ratio

7.11

EPS

₹48.76

Book Value

₹261.00

ROE

20.10%Strong

ROCE

24.00%Efficient

Dividend Yield

0.17%

Debt / Equity

0.31Moderate

Face Value

₹10.00

52W High

₹1944.00

52W Low

₹1260.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹398

▼ 77.7%downside

Trading at ₹1,783 — 78% above our estimate

BearFair valueBull

₹338₹398₹535

/100

Business quality — Solid

Growth 68Profitability 61Efficiency 40Valuation 59

Plain English

Our view

High-quality returns — 20% on equity
Low debt relative to equity
Fundamental red flags (Piotroski 1/9)

Strengths

Low debt relative to equity
Strong returns on equity (20%)
Capital is working hard (ROCE 24%)
Revenue compounding 15% over 3 years

Risks

Fundamental red flags (Piotroski 1/9)

How we got there

Fair value methods

Residual income

20% ROE fading to 13% over ~10 yrs, on ₹261 book

₹360

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹535

Analyst target

No analyst coverage

—

Blended fair value₹398

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (20%)
Capital is working hard (ROCE 24%)
Revenue compounding 15% over 3 years
Profit growing 19% a year
Promoters hold a controlling stake

Bear case

Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

36.6Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

20.1%Strong

Above 15% is considered healthy for Indian equities

ROCE

24.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.31Moderate

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹33,810 Cr

P/B

7.11

EPS

₹48.76

Div Yield

0.17%

What changed

Recent changes

Foreign investors-0.2% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 36.6×

Growth

Strong

+15% rev CAGR

Profitability

Excellent

20.1% ROE

Financial health

Comfortable

D/E 0.31

Momentum

N/A

No technicals

Today

Trading activity

Delivery %28.9%

Turnover₹4284.26L Cr

Trades26,623

VWAP₹1786.33

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+15.4%

+12.8%

10Y

—

Profit

+18.8%

+17.6%

10Y

—

EPS

+18.3%

+16.1%

10Y

—

Profile

Cons

Stock is trading at 7.06 times its book value

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.24 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

78%

Promoter

Promoters

77.9%0.00

Public

12.7%+0.26

FII / FPI

3.4%-0.24

DII

6.1%0.00

Total shareholders

1,22,189+3,326 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter77.87%

FII3.35%

DII6.10%

Public12.69%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1981, Emcure Pharmaceuticals Ltd manufactures and markets pharmaceutical products globally[1]